Medication info
Olostan Tablet 20/5 mg (Olmesartan Medoxomil, Rosuvastatin)

Olostan Tablet 20/5 mg (Olmesartan Medoxomil, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP) × 3, 30 tablets/bottle
Approval status
Active

MFDS item code 201400806 · Approved 2014.02.21 · Insurance code 641605770

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 40mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Older adults No dose adjustment is necessary when administering this medicine to adults 65 years of age or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased up to a maximum of 20mg daily. Use is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams once daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this medicine (a fixed-dose combination with the same amounts of each individual active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in children younger than 18 years.

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take both Olmesartan Medoxomil and Rosuvastatin. Olmesartan Medoxomil primarily helps treat essential hypertension. Rosuvastatin is used as an adjunct therapy for hypercholesterolemia and various forms of dyslipidemia when dietary measures and exercise are insufficient. It also contributes to delaying the progression of atherosclerosis and reducing the risk of cardiovascular events such as stroke and myocardial infarction in patients at high risk for specific cardiovascular diseases. Therefore, this medication is used to manage both hypertension and hyperlipidemia simultaneously, aiding in the prevention and treatment of cardiovascular diseases.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 40mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. 2. Older adults No dose adjustment is necessary when administering this medicine to adults 65 years of age or older. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. For patients with moderate hepatic impairment, the recommended initial dose is 10mg once daily, which may be increased up to a maximum of 20mg daily. Use is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams once daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. For patients taking olmesartan medoxomil and rosuvastatin concomitantly, they may switch to this medicine (a fixed-dose combination with the same amounts of each individual active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in children younger than 18 years.

Precautions

This medication can cause severe harm to the fetus during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients with known allergies to this medication or its components should not take it, and pregnant or potentially pregnant women, as well as breastfeeding women, should avoid taking it. Patients with very poor renal function or those receiving renal dialysis, patients with severe hepatic impairment, patients with biliary obstruction, patients with active liver disease, and patients with muscle disorders should not use this medication. In particular, a dosage of 40 mg of Rosuvastatin is contraindicated in patients at risk of myopathy or rhabdomyolysis. This medication contains lactose; therefore, patients with lactose intolerance or related genetic diseases should not take it. When administered to patients with reduced blood volume or low salt, there is a risk of initial hypotension, so they must be monitored closely. Patients with renal problems, kidney transplant recipients, patients with renal artery hypertension, and patients at risk of hyperkalemia should be administered this medication cautiously. Special precautions are required for patients with aortic stenosis and mitral valve stenosis, and for those with obstructive heart disease. Because this medication lowers blood pressure and may cause dizziness, caution is needed when performing high-risk tasks or driving. Patients who consume excessive alcohol or have a history of liver disease should undergo regular liver function tests. If symptoms of myalgia or myopathy occur, the healthcare provider should be informed immediately, and necessary tests should be carried out, with discontinuation of the medication in severe cases. This medication may interact with other drugs, so patients must inform their healthcare provider about any other medications they are taking. Pregnant or nursing women should not take this medication, and women of childbearing age should use appropriate contraception. Safety and efficacy have not been established in children under 18 years of age. Elderly patients may have higher drug concentrations, so dosage adjustment may be necessary. In case of overdose, symptoms like hypotension and palpitations may appear, and immediate medical attention should be sought. This medication should be kept out of reach of children and should not be transferred to another container.

Side effects

Elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, thoracic pain, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, vascular edema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, postural dizziness, increased blood pressure, low back pain, diarrhea, cough, epistaxis, upper respiratory tract infection, asthma, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, myopathy, myositis, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, hematuria, edema, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. This helps ensure the medication's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP) × 3, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.